CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Bruce Ruggeri, Craig A. Dionne, Susan Jones‐Bolin, Kathryn Hunter, John T. Isaacs(Brady (Norway)), John P. Mallamo, Paweł Dobrzański, Bernard Bourie(Johns Hopkins University), Robert L. Hudkins(State Street (United States)), Mark A. Ator, Mark S. Albom, Andres J. Klein–Szanto, Lisa D. Aimone, Paul Schaeffer, Pierre Casellas(Sanofi (France)), Françoise Bono(Sanofi (France)), Candy Robinson, Hong Chang, Роберто Пили(Sidney Kimmel Cancer Center), Thelma S. Angeles, Diane E. Gingrich

PubMed

September 15, 2003

Cited by 124

Related Papers

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions

|Nature Medicine|2001|1.7k

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

|Proceedings of the National Academy of Sciences|2008|723

Skin Tumor-Promoting Activity of Benzoyl Peroxide, a Widely Used Free Radical-Generating Compound

|Science|1981|507

Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells

|JCI Insight|2017|444

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery

|ACS Chemical Neuroscience|2011|436